Search filters
Filters
Clear All

Phase

  • 4
  • 4
  • 2
  • 1
  • 6
  • 43
  • 60
  • 46
  • 3
  • 57

Found 60 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopenia (ITP) patients who failed steroids

99 years and younger
All genders
PURPOSE The overall objective is to demonstrate that the addition of ianalumab (either 3mg/kg or 9mg/kg dosage) to standard care (eltrombopag) is more effective and safer compared to the standard of care (eltrombopag) alone. Primary outcome variable is determined by the time to treatment failure which is in turn determined …
Learn More

EA9181 A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

99 years and younger
All genders
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from …
Learn More

UPCC 15520: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy

99 years and younger
All genders
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Eligible subjects are those with advanced or metastatic undifferentiated …
Learn More

UPCC 18223: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed o

99 years and younger
All genders
This is a phase 1 first in human, dose escalation trial in subjects with advanced pancreatic cancer previously treated with 5-Fluorouacil-based Chemotherapy but never exposed to therapeutic gemcitabine.
Learn More

UPCC 11924: An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

99 years and younger
All genders
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …
Learn More

UPCC 01523: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treat

99 years and younger
All genders
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic …
Learn More

Aqueous Humor Proteomics

99 years and younger
All genders
PURPOSE The goal of this study is to measure the levels of over 11,000 proteins in the aqueous humor and correlate it with single-cell transcriptomics data. This will improve understanding of the molecular mechanisms and cell types contributing to dry AMD, POAG, and Stargardts disease. This will allow us to …
Learn More

UPCC 16423: Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid l

99 years and younger
All genders
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. We would like to rely on WCG as the IRB of record for this study.
Learn More

NRG-BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

99 years and younger
All genders
To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 …
Learn More

NGT Pilot Study

99 years and younger
All genders
PURPOSE To perform a pivotal study of the next-generation tomosynthesis system with volunteers recruited among women with suspicious breast finding(s), with the goal of assessing the effect of scanning method on characterization of findings as benign or malignant. The primary outcome variable for this 3D mammography imaging study is the …
Learn More
41 - 50 of 60